Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) released its earnings results on Monday. The company reported ($2.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.50), FiscalAI reports. The firm had revenue of $17.23 million during the quarter, compared to analysts’ expectations of $16.32 million. Tonix Pharmaceuticals had a negative return on equity of 68.99% and a negative net margin of 548.64%.
Tonix Pharmaceuticals Stock Performance
Shares of TNXP stock opened at $4.74 on Monday. The firm’s 50 day moving average is $8.71 and its 200 day moving average is $12.21. The stock has a market capitalization of $81.29 million, a P/E ratio of -0.37 and a beta of 1.90. Tonix Pharmaceuticals has a 12 month low of $4.55 and a 12 month high of $20.56.
Analyst Upgrades and Downgrades
TNXP has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. Raymond James Financial reissued a “strong-buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, October 20th. Wall Street Zen raised Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, October 4th. Finally, Canaccord Genuity Group initiated coverage on Tonix Pharmaceuticals in a research note on Monday, October 26th. They issued a “buy” rating and a $18.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tonix Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $22.33.
Read Our Latest Stock Report on TNXP
Insiders Place Their Bets
In other Tonix Pharmaceuticals news, CEO Seth Lederman acquired 2,000 shares of Tonix Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average cost of $13.79 per share, for a total transaction of $27,580.00. Following the purchase, the chief executive officer owned 11,005 shares of the company’s stock, valued at approximately $151,758.95. This represents a 22.21% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.00% of the company’s stock.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving the central nervous system, immunology and infectious diseases. The company’s research programs are designed to address disorders with significant unmet medical needs, including chronic pain, neuropsychiatric conditions and infectious diseases.
Tonix’s pipeline has included TNX-102 SL, an investigational sublingual formulation of cyclobenzaprine being studied for fibromyalgia and other pain-related conditions.
Featured Stories
- Five stocks we like better than Tonix Pharmaceuticals
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
